Historic: Brazil Approves World's First Single-Dose Dengue Vaccine - Video

Brazil has approved the world’s first single-dose dengue vaccine, marking a historic milestone as dengue cases rise globally amid climate change. The vaccination, known as Butantan-DV, was developed by the Butantan Institute in São Paulo and authorized by Brazil’s health regulatory agency ANVISA for people aged 12 to 59. Unlike the current vaccine TAK-003, which requires two doses three months apart, Butantan-DV’s single dose allows for quicker, easier vaccination efforts.

After eight years of clinical trials involving over 16,000 volunteers, the vaccine showed 91.6% efficacy against severe dengue. Dengue, spread by Aedes mosquitoes and known as “breakbone fever,” caused a record 14.6 million cases worldwide in 2024, with half of the deaths occurring in Brazil. The country has partnered with Chinese company WuXi Biologics to secure around 30 million doses for delivery in late 2026, aiming to combat the disease’s growing threat driven by global warming, reports Folha De S.Paulo.